Oxytetracycline

…2.2 | Trial location and design As Moore-Oxy® (MO; oxytetracycline HCL 5%, Hebei Kexing Pharmaceutical Co. Ltd., Shijiazhuang City, China) was the reference This clinical trial was conducted between the 5th…

illance. MATERIALS AND METHODS Trial location and design This clinical trial was conducted between the 5th of November and the 5th of December 2019 in Ngaoundere II, Ngaoundere III and Martap subdivisions in the Vina Division of the Adamawa plateau. Around 40% of the cattle population of Cameroon is located in the Adamawa region (MINEPIA, 2013). Ngaoundere is the 2 capital of the Adamawa region, with geo-referenced coordinates between 6° 40’ 0” and 7° 30’ 0” north latitude and between 13° 20’ 0” and 14° 10’ 0”’east longitude (Fig. 1). An FMD outbreak in the municipalities of Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029789.93744641 — This a preprint and has not been peer reviewed. Data may be preliminary. Ngaoundere II, Ngaoundere III and Martap was advised to the lead author by a field technician in Ngaoundere on the 4th of November 2019. The following day, the outbreak areas were accessed, and the treatment trials commenced immediately. Two teams of two members each were formed to enable animal treatments and follow-up of the treated cases. Participating farms were selected following demonstration of owner willingness to participate, and included: Horé Mayanga, Borongo, Tchabal Baouro and Mbidjoro. The GPS data of all farms was recorded. As Moore-Oxy® (manufactured in China; MO) was the reference antibiotic commonly used by farmers to manage clinical FMD in the study area, it was decided to compare the efficacy of this formulation on the healing of FMD lesions with that of TS. As MO is administered intra-muscularly and TS is administered topically, on each farm, three animals were matched by age and breed, with similar

…Prophylactic systemic antibiotic treatment was given in the form of an intramuscular (IM) injection of 30 mg/kg of long-acting oxytetracycline (ENGEMICINA D.D., MSD, MSD Italia S.r.l., Roma…

…The intra- assay coefficient of variation (CV) for samples containing 176.5, (oxytetracycline at 10 mg/kg) prior to mulesing. Blood samples 81.9 and 34.8 nmol/L cortisol respectively, were…

…Prophylactic systemic antibiotic treatment was given in the form of an in- tramuscular (IM) injection of 30 mg/kg of long-acting oxytetracycline (ENGEMICINA Animals 2023, 13, 407 D.D., MSD, MSD…

ease diagnosis is usually based on clinical presenta­ As TS has a pH of 2.7, it has a potential viricidal impact tion. However, laboratory testing and confirmation may be that may reduce transmission risks, with the formulation critical as some of the differential diagnoses are notifiable potentially aiding healing and avoiding the need for other diseases, especially foot-and-mouth disease (FMD), blue­ treatments, including antibiotics.11,12 This paper describes tongue (BT), sheep pox and peste des petits ruminants a preliminary investigation of orf therapy with TS, exam­ For personal use only. (PPR). Laboratory diagnosis can be achieved through elec­ ining the potential antiviral roles and healing properties of tron microscopy, PCR based on the amplification of B2L4 the pain-relief formulation in naturally infected lambs with or VIR5 genomic regions, and/or, isolation of the virus in orf, through viral genome real-time PCR quantification cell culture using a variety of primary and continuous cell and tissue culture in ovine primary cells. lines. Vaccination is the preferred option to control the dis­ Materials and Methods ease. Live virus and attenuated vaccines usually provide All procedures were conducted under Project Licence PI adequate protection against orf virus, albeit not life-long, 40/19 approved by the Ethics Committee for Animal with their annual administration considered the best strat­ Experiments from the University of Zaragoza. The care egy to control the disease in flocks and herds.6 However, and use of animals were performed according to the orf vaccine is currently unavailable in most European Spanish Policy for Animal Protection RD53/2013, meeting countries, and where available, existing live-attenuated or the European Union Directive 2010/63